- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...

The“Global Filgrastim Injection market Research Report 2022 to 2027”, the study focuses on the analysis of historical and current market trends, which serves as a foundation for assessing industry ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...